UMIN-CTR Clinical Trial

Basic information
Official scientific title of the study	Quality of Systematic Reviews Underlying Clinical Practice Guidelines
Title of the study (Brief title)	Quality of Systematic Reviews underlying Clinical Practice Guidelines for Schizophrenia
Region	North America

Condition
Condition	Methodological Quality and completeness of reporting as represented by the AMSTAR tool and PRISMA checklist
Classification by specialty	Psychiatry
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	The purpose of this study is to assess the methodological quality and completeness of reporting in Systematic Reviews underlying current Clinical Practice Guidelines for Schizophrenia across professional organizations both domestic and international.
Basic objectives2	Others
Basic objectives -Others	To assess the methodological quality and completeness of reporting in Systematic Reviews underlying Clinical Practice Guidelines for Schizophrenia.
Trial characteristics_1	Others
Trial characteristics_2	Others
Developmental phase	Not applicable

Assessment
Primary outcomes	Global Methodological Quality and Completeness of Reporting of Clinical Practice Guidelines as represented by underlying systematic reviews graded with the AMSTAR tool and PRISMA checklist, respectively
Key secondary outcomes	Proportion of recommendations in CPGs with underlying evidence based on Systematic Reviews vs proportion of recommendations not based on systematic reviews. Quality of evidence underlying key specific recommendations as represented by methodological quality and completeness of reporting of systematic reviews used for each key recommendation.

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type	Others,meta-analysis etc

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit	Not applicable
Age-upper limit	Not applicable
Gender	Male and Female
Key inclusion criteria	Clinical Practice Guidelines: 1. Clinical Practice Guidelines must be recognized by a national governmental or provider/professional organization. 2. Clinical Practice Guidelines must be in English. 3. Clinical Practice Guidelines must contain recommendations relevant to best practices in the diagnosis, treatment, and/or management of Schizophrenia. Systematic Reviews: 1. Systematic Reviews must be in English. 2. Systematic Reviews must be peer-reviewed and published, or currently in press. 3. The Systematic Review must have performed a systematic search and synthesis of available evidence.
Key exclusion criteria	Clinical Practice Guidelines: 1. Clinical Practice Guidelines without reference lists and those without readily accessible reference lists such as those only accessible by email correspondence will be excluded. 2. Addendums published relevant to one or more recommendations for a CPG will be excluded. 2. CPGs not recognized by a professional organization or governmental body will be excluded. Systematic Reviews: 1. Systematic reviews of animal studies will be excluded.
Target sample size	100

Research contact person
Name of lead principal investigator	Matt Vassar
Organization	Oklahoma State University Center for Health Sciences
Division name	College of Osteopathic Medicine
Address	1111 W. 17th St.
TEL	918-582-1972
Email	matt.vassar@okstate.edu

Public contact
Name of contact person	Matt Vassar
Organization	Oklahoma State University Center for Health Sciences
Division name	College of Osteopathic Medicine
Address	1111 W. 17th St.
TEL	918-582-1972
Homepage URL	http://www.healthsciences.okstate.edu
Email	matt.vassar@okstate.edu

Sponsor
Institute	Oklahoma State University Center for Health Sciences
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization	N/A
Organization
Division
Category of Funding Organization	Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funｄer(s)

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2016 Year 08 Month 01 Day

Progress
Recruitment status	Completed
Date of protocol fixation	2016 Year 07 Month 01 Day
Anticipated trial start date	2016 Year 07 Month 04 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results	Unpublished
URL releasing results
Results
Other related information	No other related information

Management information
Registered date	2016 Year 07 Month 11 Day
Last modified on	2016 Year 07 Month 11 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026624